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Abstract The hereditary spastic paraplegias (HSPs) are a
group of genetic conditions in which spastic paralysis of
the legs is the principal clinical feature. This is caused by a
relatively selective distal axonal degeneration involving the
longest axons of the corticospinal tracts. Consequently,
these conditions provide an opportunity to identify genes,
proteins and cellular pathways that are critical for axonal
health. In this review, we will provide a brief overview of
the classification, clinical features and genetics of HSP,
highlighting selected HSP subtypes (i.e. those associated
with thin corpus callosum or cerebellar ataxia) that are of
particular clinical interest. We will then discuss appropriate
investigation strategies for HSPs, suggesting how these
might evolve with the introduction of next-generation
sequencing technology. Finally, we will discuss the man-
agement of HSP, an area somewhat neglected by HSP
research.
Keywords Hereditary spastic paraplegia  Axonal
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Introduction
The hereditary spastic paraplegias (HSPs) are a group of
genetic conditions in which spastic paralysis of the legs is
the principal clinical feature [1, 2]. In most subtypes of
HSP, this is caused by a relatively selective distal axonal
degeneration involving the longest axons of the cortico-
spinal tracts [3]. As a group, these conditions are moder-
ately rare, with prevalence estimates in different
geographical regions ranging from 0.1 to 9.6 per 105 [4].
However, as they are chronic and sometimes severe con-
ditions that frequently present in childhood and young
adult life, they represent a significant disease burden. In
addition, they are scientifically important, since they pro-
vide an opportunity to identify genes, proteins and cellular
pathways that are critical for axonal health.
In this review, we will provide a brief overview of the
classification, clinical features and genetics of HSP, high-
lighting selected HSP subtypes that are of particular clin-
ical interest. We will then discuss appropriate investigation
strategies for HSPs, suggesting how these might evolve
with the introduction of next-generation sequencing tech-
nology. Finally, we will discuss the management of HSP,
an area somewhat neglected by HSP research.
Overview of main HSP clinical categories
Traditionally, the hereditary spastic paraplegias are sub-
categorised into ‘‘pure’’ and ‘‘complex’’ (or ‘‘complicated’’)
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subtypes [3]. In northern European populations, pure forms
are the most frequent. The clinical features of pure HSP
have been thoroughly described in previous research arti-
cles and reviews, and diagnostic criteria have been pro-
posed [1, 5–9]. Briefly, the typical clinical picture is of a
slowly progressive, predominantly symmetrical, spastic
paraplegia. This is frequently accompanied by minor sen-
sory abnormalities (such as absent vibration sensation) and
neurological bladder involvement, but bowel involvement
is rare. If seen at all, arm involvement is minimal and does
not extend beyond hyper-reflexia and minor weakness (e.g.
difficulty unscrewing a tight bottle top); more significant
arm involvement should raise the possibility of alternative
diagnoses such as primary lateral sclerosis or amyotrophic
lateral sclerosis, while bulbar involvement is incompatible
with a diagnosis of pure HSP. Age at onset varies from
childhood to late adult life. Within many multiplex families
it is highly variable, although mutations in certain genes,
notably spastic paraplegia gene (SPG) 3A/atlastin1, are
predominantly associated with a childhood age at onset.
While pure HSPs present a relatively homogenous
clinical picture, complex HSPs are a disparate group of
distinct disorders (Table 1) [1–3]. As most complex HSPs
are inherited in an autosomal recessive pattern, they are the
commonest forms of HSP in populations where consan-
guinity is frequent; for example, in a Tunisian series of 38
families, approximately 70 % of families had autosomal
recessive complex HSP [10]. However, it is important to
recognise that these complex subtypes of HSP are found
worldwide, e.g. HSP with thin corpus callosum caused by
SPG11 or SPG15 mutations has been described in many
populations and is the most common type of complex HSP
that we see in our own clinical practice in Cambridge, UK.
Genetics of HSPs
The HSPs show a remarkable degree of genetic heteroge-
neity. The chromosomal location of more than 70 SPGs is
known, and presently more than 50 of the genes have been
fully identified (Table 1). Moreover, additional syndromes
such as Warburg Micro syndrome, previously considered
distinct, have recently been incorporated under the rubric
of HSP by reason of overlapping cellular pathology [11].
This new knowledge has led to an evolution of the clas-
sification of HSP, which, while still referring to phenotypic
information, is increasingly focussed on the gene involved.
In addition, gene identification has resulted in the distinc-
tion between pure and complex HSP becoming somewhat
blurred as it has become apparent that mutations in the
same gene may cause either a pure or complex phenotype.
An example of this is the rare identification of mutations in
SPG4/SPAST, SPG31/REEP1 or SPG3A/atlastin1, three
genes typically associated with pure HSP, in patients who
have spastic paraplegia accompanied by cerebellar ataxia
or peripheral neuropathy [12–14].
Pure HSP phenotype
In northern European populations, autosomal dominant
inheritance accounts for the majority of patients from
families with pure HSP [15]. Autosomal recessive inher-
itance accounts for most of the remainder, while clear-cut
X-linked inheritance is infrequent. Rarely, gonadal
mosaicism for a dominant gene has been described and
this can be mistaken for autosomal recessive inheritance
[16]. In addition, some patients present without a family
history. Potential genetic explanations for this are varied
and include singleton autosomal recessive cases, new
autosomal dominant mutations, or inherited autosomal
dominant mutations with non-penetrance in a parent. The
estimated relative frequency of mutations in selected
genes associated with pure HSP is given in Table 2. From
this table, it can be seen that testing for three genes,
SPG4/SPAST, SPG3A/Atlastin1 and SPG31/REEP1, will
identify the responsible mutation in approximately 50 %
of families with autosomal dominant pure HSP. For SPG4/
SPAST, this testing should include methodologies to pick
up whole exon deletions, as these are a common muta-
tional class in this subtype of HSP (they have also been
described in other forms including SPG3A/Atlastin1 and
SPG31/REEP1-HSP) [14, 17–19]. For families with an
autosomal recessive inheritance pattern, screening SPG5
(CYP7B1) will pick up the causative mutations in
approximately 5–10 % of cases. However, the yield from
testing each individual additional gene beyond these
commoner genes is low. Using traditional ‘‘one at a time’’
sequential gene testing to detect these rare mutations can
be very expensive and may not be justifiable for publically
funded health services. Next-generation sequencing
approaches are currently revolutionising this situation (see
below).
Complex HSP phenotypes
As mentioned above, the complex HSPs are a diverse set of
conditions, each with distinctive clinical features and each
caused by one or a small set of genes. Here, we will focus
on two of the more common presentations, HSP with thin
corpus callosum and HSP accompanied by cerebellar
ataxia.
HSP with thin corpus callosum
A thin corpus callosum on MRI scanning is a characteristic
feature of patients who have autosomal recessive SPG11
J Neurol
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Table 1 List of known or probable HSP genes
Gene Protein Inherited OMIM Comment P/C* Clinical features of complex forms
SPG1/
L1CAM
L1-cell adhesion molecule XL #303350 C 1. MASA syndrome, 2. X-linked
hydrocephalus, 3. X-linked
complicated HSP
SPG2/PLP1 Proteolipid protein 1 XL #312920 P/C 1. Pure HSP, 2. complex HSP, 3.
Pelizaeus–Merzbacher disease
SPG3A/
ATL1
Atlastin1 AD #182600 P
SPG4/SPAST Spastin AD #182601 P
SPG5A/
CYP7B1
25-hydroxycholesterol 7-alpha-
hydroxylase
AR #270800 P
SPG6/NIPA1 NIPA1 AD #600363 P
SPG7 Paraplegin AR #607259 P/C Cerebellar ataxia, optic atrophy,
deafness, amyotrophy
SPG8/
KIAA0196
Strumpellin AD #603563 P
SPG9 – AD %601162 C Cataracts, motor neuropathy, skeletal
abnormalities and gastro-
oesophageal reflux.
SPG10/
KIF5A
Kinesin heavy chain 5A AD #604187 P/C Peripheral neuropathy, amyotrophy,
mental retardation, parkinsonism
SPG11 Spatacsin AR #604360 C HSP with thin corpus callosum.
Peripheral neuropathy, intellectual
disability, cognitive decline,
amyotrophy, pseudobulbar
involvement, cerebellar
involvement, parkinsonism,
dystonia
SPG12/RTN2 Reticulon2 AD #604805 P
SPG13/
HSPD1
Heat shock 60 kDa protein 1 AD #605280 P
SPG14 – AR %605229 C Intellectual disability, motor
neuropathy
SPG15 Spastizin AR #270700 C HSP with thin corpus callosum.
Peripheral neuropathy, intellectual
disability, cognitive decline,
amyotrophy, pseudobulbar
involvement, cerebellar
involvement, parkinsonism,
dystonia, pigmentary maculopathy
(Kjellin syndrome).
SPG16 – XLR %300266 C Spastic quadraplegia, intellectual
disability, cerebellar ataxia, optic
atrophy, nystagmus, bowel and
bladder dysfunction.
SPG17/
BSCL2
Seipin AD #270685 C Silver syndrome; HSP with distal
amyotrophy. Overlaps with HMSN
V.
SPG18/
ERLIN2
ER lipid raft associated 2 AR #611225 C Epilepsy, intellectual disability,
pseudobulbar palsy, joint
contractures
SPG19 AD %607152 P
SPG20/
SPARTIN
Spartin AR #275900 C Troyer syndrome: dysarthria,
pseudobulbar palsy, intellectual
disability, amyotrophy, short stature
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Table 1 continued
Gene Protein Inherited OMIM Comment P/C* Clinical features of complex forms
SPG21/
MAST
Maspradin AR #248900 C Mast syndrome: progressive
dementia, cerebellar signs, extra-
pyramidal involvement, thin corpus
callosum.
SPG22 SLC16A2 XLR #300523 C Allan-Herndon-Dudley syndrome
SPG23 – AR %270750 C Disordered skin pigmentation,
peripheral neuropathy
SPG24 – AR %607584 P
SPG25 – AR %608220 C Disc herniation
SPG26/
B4GALNT1
Beta-1,4 N-
acetylgalactosaminyltransferase
1
AR #609195 C Intellectual disability, peripheral
neuropathy, dysarthria, cerebellar
signs, extrapyramidal involvement,
cortical atrophy
SPG27 – AR %609041 P
SPG28/
DDHD1
Phospholipase DDHD1 AR #609340 P/C Cerebellar eye signs, peripheral
neuropathy
SPG29/
KIF1A
Kinesin family member 1A AD %609727 Sensorineural hearing impairment,
neonatal hyperbilirubinemia, hiatus
hernia
SPG30 – AR #610357 C Cerebellar signs, peripheral
neuropathy
SPG31/
REEP1
Receptor expression-enhancing
protein 1
AD #610250 P
SPG32 – AR %611252 C Cognitive impairment, thin corpus
callosum, cortical atrophy,
cerebellar atrophy, pontine
dysraphia.
[SPG33/
ZFYVE27]
[Protrudin] [AD] #610244 Mutation may not
be pathogenic-
present in
control
populations
[P]
SPG34 – XLR %300750 P
SPG35/FA2H Fatty acid 2-hydroxylase AR #612319 C Dysarthria, intellectual decline,
leukodystrophy, dystonia, optic
atrophy, seizures, cerebellar signs,
thin corpus callosum. May cause
brain iron accumulation.
SPG36 – AD %613096 C Lower limb sensory changes
SPG37 – AD %611945 P
SPG38 – AD %612335 C Similar to Silver syndrome (see
SPG17)
SPG39/
PNPLA6
Neuropathy target esterase AR #612020 C Distal amyotrophy, cerebellar
atrophy. Allelic with Boucher–
Neuhauser syndrome
(spinocerebellar ataxia,
hypogonadotropic hypogonadism,
chorioretinal dystrophy)
SPG40 –
SPG41 – AD %613364 Single family
with lod score
\3
SPG42/
SLC33A1
Acetyl-coenzyme A transporter 1 AD #612539 P
SPG43/
C19orf12
C19orf12 AR #615043 P/C Upper limb involvement, distal
amyotrophy. May also be associated
with brain iron accumulation
J Neurol
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Table 1 continued
Gene Protein Inherited OMIM Comment P/C* Clinical features of complex forms
SPG44/GJC2 Gap junction gamma-2 protein AR #613206 C Cerebellar signs, seizures, cognitive
impairment, scoliosis,
leukodystrophy, thin corpus
callosum.
SPG45/
NT5C2
Cytosolic purine 5’-nucleotidase AR #613162 C Optic atrophy, thin corpus callosum,
intellectual disability
SPG46/GBA2 Non-lysosomal
glucosylceramidase
AR #614409 C Cerebellar signs, intellectual
impairment, cerebral atrophy,
cerebellar atrophy, thin corpus
callosum, pseudobulbar
involvement, cataracts.
SPG47/
AP4B1
AP-4 complex subunit beta-1 AR #614066 C Neonatal hypotonia, severe
intellectual impairment, dysmorphic
features, thin corpus callosum.
SPG48/
AP5Z1
AP-5 complex subunit zeta-1 AR #613647 C Urinary incontinence
SPG49/
TECPR2
Tectonin beta-propeller repeat-
containing protein 2
AR #615031 C Intellectual impairment, dysmorphic
features, cerebral atrophy,
cerebellar atrophy, thin corpus
callosum
SPG50/
AP4M1
AP-4 complex subunit mu-1 AR #612936 C Neonatal hypotonia, severe
intellectual impairment,
pseudobulbar signs, microcephaly,
cerebellar atrophy
SPG51/
AP4E1
AP-4 complex subunit epsilon-1 AR #613744 C Neonatal hypotonia, severe
intellectual impairment,dysmorphic
features, seizures, cortical atrophy,
cerebellar atrophy, microcephaly
SPG52/
AP4S1
AP-4 complex subunit sigma-1 AR #614067 C Neonatal hypotonia, severe
intellectual impairment,
microcephaly, dysmorphic features,
short stature
SPG53/
VPS37A
Vacuolar protein sorting-
associated protein 37A
AR #614898 C Intellectual disability
SPG54/
DDHD2
Phospholipase DDHD2 AR #615033 C Intellectual disability, dysarthria,
dysphagia, optic hypoplasia, thin
corpus callosum and white matter
changes, short stature
SPG55/
C12ORF65
C12orf65 AR #615035 C Peripheral neuropathy, optic atrophy,
intellectual disability
SPG56/
CYP2U1
Cytochrome P450 2U1 AR #615030 P/C Upper limb involvement, peripheral
neuropathy, intellectual
impairment, thin corpus callosum
SPG57/TFG Protein TFG AR #615658 C Optic atrophy, peripheral neuropathy
SPG58/
SPAX2/
KIF1C
Kinesin-like protein KIF1C AR #611302 C Cerebellar ataxia
SPG59/USP8 Ubiquitin carboxyl-terminal
hydrolase 8
AR *603158 VUS P
SPG60/
WDR48
WD repeat-containing protein 48 AR *612167 VUS C Nystagmus, peripheral neuropathy,
intellectual disability
SPG61/
ARL6IP1
ADP-ribosylation factor-like
protein 6-interacting protein 1
AR #615685 C Peripheral neuropathy
SPG62 –
SPG63/
AMPD2
AMP deaminase 2 AR #615686 P/C White matter changes in corpus
callosum
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and SPG15 mutations. These patients have a variable
combination of clinical features which, as well as thin
corpus callosum, includes typically childhood or teenage
onset spastic paraplegia, learning difficulties with pro-
gressive cognitive decline, cerebellar signs, ocular
involvement, peripheral motor axonopathy and extrapyra-
midal features including parkinsonism. SPG11/15 muta-
tions are associated with relatively severe gait involvement
and patients often eventually require a wheelchair. It is
important to note that a thin corpus callosum is not a
universal finding in SPG11/15 HSP (e.g. in large series, it
was found in 90 % of SPG11 cases and 60 % of SPG15
patients), and that learning difficulties may be present
before the spastic gait develops [20–22].
Cell biological studies on the SPG11 and SPG15 pro-
teins have revealed why mutations in these genes lead to a
similar clinical phenotype. Both SPG11 and SPG15 pro-
teins interact with a 4-protein complex termed AP5
(adapter protein 5), which localises to small intracellular
membrane-bound vesicles called endosomes [23, 24].
Although AP5’s function is not fully understood, it prob-
ably acts to sort membrane cargoes away from the endo-
somal compartment [23, 24]. Intriguingly, recessive
mutations in a component of the core AP5 complex
Table 1 continued
Gene Protein Inherited OMIM Comment P/C* Clinical features of complex forms
SPG64/
ENTPD1
Ectonucleoside triphosphate
diphosphohydrolase 1
AR #615683 C Dysarthria, intellectual disability,
microcephaly, delayed puberty
SPG65 Duplicate of SPG45
SPG66/ARSI Arylsulfatase I AR *610009 VUS C Thin corpus callosum, cerebellar
hypoplasia, colpocephaly,
peripheral neuropathy
SPG67/
PGAP1
GPI inositol-deacylase AR *611655 VUS C Intellectual disability, tremor, absent
corpus callosum, defective
myelination
SPG68/
FLRT1
leucine-rich repeat
transmembrane protein FLRT1
AR *604806 VUS C Optic atrophy, peripheral neuropathy
SPG69/
WARBM2/
RAB3GAP2
Rab3 GTPase-activating protein
non-catalytic subunit
AR *609275 C Warburg micro syndrome, Martsolf
syndrome
SPG70/
MARS
Methionine-tRNA ligase,
cytoplasmic
AR *156560 VUS P/C Mild intellectual disability
SPG71/ZFR Zinc finger RNA-binding protein AR *615635 VUS C Thin corpus callosum
SPG72/
REEP2
Receptor expression-enhancing
protein 2
AR/AD #615625 P
Spastic
ataxias
SPAX1/
VAMP1
Vesicle-associated membrane
protein 1
AD #108600 SPAX
SPAX2/
SPG58/
KIF1C
Kinesin-like protein KIF1C AR #611302 SPAX
SPAX3/
MARS2
Methionine-tRNA ligase,
mitochondrial
AR #611390 SPAX
SPAX4/
MTPAP
Poly(A) RNA polymerase,
mitochondrial
AR #613672 SPAX
SPAX5/
AFG3L2
AFG3-like protein 2 AR #614487 SPAX
SPAX6/
SACS
Sacsin AR #270550 SPAX Spastic ataxia of Charlevoix-
Saguenay
EXOSC3/
PCH1B
Exosome complex component
RRP40
AR *606489 Allelic with
pontocerebellar
hypoplasia
Note that sometimes the distinction between pure and complex HSP may be somewhat arbitrary. See OMIM entries (http://www.ncbi.nlm.nih.
gov/omim/) for the appropriate primary literature
AD autosomal dominant, AR autosomal recessive, C complex, HMSN hereditary motor and sensory neuropathy, P pure, SPAX spastic ataxia,
VUS variant of uncertain significance
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(SPG48/AP5Z1) also cause a very similar clinical pheno-
type to SPG11/15 mutations, with cognitive defects, thin
corpus callosum and spastic paraplegia [25]. Thus, HSP
with thin corpus callosum is an excellent example of the
principle that diseases with similar phenotypes are often
caused by mutations in functionally related genes. At least
four other subtypes of recessive HSP may also present with
thin corpus callosum, SPG21/Maspardin, SPG35/FA2H
and SPG46/GBA2 and SPG54/DDHD2 ([25] and see
Table 1); it remains to be seen whether any of the encoded
proteins are functionally related to the AP5 complex.
HSP with cerebellar ataxia
Patients who present with a mixed cerebellar ataxia and
spastic paraplegia phenotype represent a particular diag-
nostic challenge, as the differential diagnosis is very broad.
It can be helpful to first make a decision as to whether
spastic paraplegia or cerebellar ataxia is the dominant
feature. There are consensus diagnostic pathways for
patients with predominant cerebellar ataxia and we will not
review these further here [26]. In patients where spastic
paraplegia is the predominant feature, it is useful to sub-
divide into pure and complex subtypes, analogous to the
subdivision of HSP.
‘‘Complex’’ spastic ataxia in which the cerebellar ataxia
is a (sometimes variable) feature of a more complex syn-
dromal picture. Such conditions include HSP with thin
corpus callosum (SPG11/15 mutations), SPG35/FA2H-
associated HSP, Troyer syndrome (SPG20) and Mast
syndrome (SPG21), SPG26/B4GALNT1, SPG30/KIF1A,
SPG39/PNPLA6 and SPG46/GBA2. This group also con-
tains a variety of rare metabolic conditions (reviewed in
[27, 28]), including cerebrotendinous xanthomatosis, triple
H syndrome, cerebral folate deficiency, metachromatic
leukodystrophy, Type III 3-methylglutaconic aciduria, as
well as other conditions such as Alexander disease and
vanishing white matter disease. Rare patients with Chedi-
ak–Higashi syndrome (caused by mutations in the lyso-
somal trafficking regulator LYST gene) may also present
with spastic paraplegia, cerebellar ataxia and peripheral
neuropathy, without the hypopigmentary or immune defi-
ciency typically associated with this condition [29].
‘‘Pure’’ spastic ataxia There are many patients in whom
spastic paraplegia with cerebellar involvement is the
exclusive clinical presentation. This can occur in three
main scenarios:
(a) As an unusual presentation of mutations in genes
that are classically associated with ‘‘pure’’ hereditary
spastic paraplegia, including autosomal dominant
SPG4/spastin and SPG31/REEP1 and autosomal
recessive SPG5/CYP7B1 [12, 14, 30].
(b) As a presentation of genes that are classically associ-
ated with cerebellar ataxia. This would especially
include Friedreich ataxia and SCA3, in which pyrami-
dal signs may be the presenting feature [31, 32].
(c) As a presentation of mutations in genes that typically
cause a spastic paraplegia/cerebellar ataxia overlap
syndrome. These genes are often classified under the
spastic ataxia (SPAX) nomenclature. Well-recogni-
sed examples include the autosomal recessive spastic
Table 2 Reported frequencies of mutations in selected pure HSP genes
Gene Reported frequency in familial cases Frequency in sporadic
cases
Frequency in unselected cases
SPG4/SPAST 31–47 % of AD-pure HSP [49–54] 7–18 % [51, 52, 55–57] 17–26 % [51, 56, 58]
SPG3A/
ATLASTIN1
8–39 % of AD-pure HSP (studies often comprised
families with early onset and screened SPG4 negative)
[51, 59–61]
Unknown 7 % (after exclusion of SPG4
mutations) [13]
SPG31/REEP1 2–8 % of AD-pure HSP (screened families typically
SPG4 and/or SPG3 negative) [62–64]
2 % [65] 3–7 % [63, 65]
SPG10/KIF5A 3–5 % (series included families with complicated HSP,
typically SPG4 and SPG3 negative). A rare cause of
pure HSP [66–68]
None detected Unknown
SPG8/KIAA0196 5–8 % of SPG3A and SPG4-negative AD HSP families
[69, 70]
Unknown Unknown
SPG12/RTN2 Rare [71] Rare Rare
SPG6/NIPA1 \1 % of AD-pure HSP [72, 73] Unknown Rare [72]
SPG13/HSPD1 Rare Unknown Unknown
SPG42/SLC33A1 Unknown (single family only) Unknown Unknown
SPG5A/CYP7B1 7 % of AR-pure HSP 1 reported AD family [30] 3 % [30] Unknown
SPG7 Rare cause of AR-pure HSP 7–12 % [34, 74] \5 % of unselected AR families
[75, 76]
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ataxia of Charlevoix-Saguenay (ARSACS; SPAX6)
and SPG7/paraplegin [33, 34]. They also include
VAMP1 (SPAX1), KIF1C gene (SPAX2/SPG58),
MARS2 (SPAX3), MTPAP (SPAX4) and AFG3L2
(SPAX5/SCA28) (Table 1) [32, 35].
Investigation of a patient with suspected HSP
The traditional approach to investigating a patient with
possible HSP is to define the phenotype and inheritance
pattern, exclude alternative causes, then attempt to make a
definitive molecular genetic diagnosis, where possible
using clinical and family history information to focus
genetic investigations appropriately.
Definition of phenotype, inheritance and exclusion
of other causes
As specific investigations of a patient with suspected HSP
depend on their clinical features and inheritance pattern,
careful clinical phenotyping of index cases and potentially
affected family members is crucial. A detailed medical
history should include developmental milestones and a
three generational family tree. Affected individuals and
ideally, apparently unaffected family members should
undergo a clinical neurological examination, to document
specific neurological features and identify asymptomatic
family members who may have subtle abnormal signs on
examination. This is particularly important for apparently
sporadic cases or isolated sibships, where positive exami-
nation findings in an asymptomatic parent will point
towards the probability of autosomal dominant inheritance.
Even in individuals who have typical clinical features of
HSP and a positive family history of spastic paraparesis, it is
important to consider alternative causes and importantly
exclude other treatable familial conditions. In his regard,
MR imaging of the brain and spinal cord is crucial and
should be undertaken in all sporadic cases and at least one
family member of familial presentations. Imaging will not
only identify many structural, inflammatory or metabolic
abnormalities but is also useful to guide investigations into
specific genetic causes (for example, by highlighting atro-
phy patterns). Note that imaging does have an appreciable
false negative rate, for example, it can be normal in certain
metabolic or inflammatory conditions, including adreno-
leukodystrophy or primary progressive multiple sclerosis.
A baseline metabolic blood screen in the index case
could include Vitamins B12 and E, creatine kinase, very
long chain fatty acids, white cell enzymes, anti-nuclear
antibody and copper levels. However, individuals with
more complex clinical features or an unclear family history
may require further baseline tests. For example, in pre-
sumed sporadic pure HSP, a set of more extensive inves-
tigations is appropriate, as an inherited basis for the disease
has not been proven. This includes CSF examination
(including oligoclonal bands, HTLV serology), Syphilis
and HIV serology as well as vasculitis screen [36–38]. An
oral short trial of Levodopa will identify those individuals
with dopa-responsive dystonia and neurophysiology can be
useful if there is an associated neuropathy or suspicion of
amyotrophic lateral sclerosis [39]. Table 3 summarises a
list of conditions to be considered in the differential diag-
nosis and investigation of sporadic pure HSP.
For those individuals in whom the above baseline
investigations are unremarkable and/or where the family
history and clinical features point towards a specific
genetic diagnosis, it is then appropriate to test for the
suspected mutation.
Genetic investigations
There is considerable clinical utility for HSP families in
detecting their causative mutation. It gives diagnostic
Table 3 Conditions and investigations to be considered in the dif-
ferential diagnosis of pure HSP
Structural and vascular
Arterio-venous dural fistula [77] MRI/angiogram
Spinal or parasagittal tumour MRI
Spondylosis MRI
Inflammatory
Multiple Sclerosis MRI, CSF
Vasculitic Myelopathy [36] Autoimmune profile
Stiff person syndrome [78] Neurophysiology, antibody
testing
Sarcoidosis [79] MRI, CSF, chest X-ray
Metabolic (acquired and hereditary)
Vitamin deficiency (B12, E) Vitamin levels
Nitrous oxide toxicity [80] History, B12 level
Adrenoleucodystrophy and other
leucodystrophies [81, 82]
White cell enzymes,
VLCFA, MRI
Copper deficiency myelopathy [83] Copper levels
Degenerative
Primary lateral sclerosis Neurophysiology and
evolution of clinical
picture
Infectious
Tropical spastic paraparesis [37] HTLV—1 serology, CSF
HIV myelopathy [38] HIV serology, CSF
Syphilis Syphilis serology, CSF
Other
Radiation myelopathy [84] History, imaging
Spinocerebellar ataxias and other
genetic conditions (see text and
[39])
Genetic testing. Trial of
l-dopa
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certainty, prevents further unnecessary investigations and
opens the possibility of predictive and prenatal testing.
However, until very recently, in many healthcare systems,
economic factors necessitated that genetic investigations
were restricted to analysis of HSP genes in which there was
the highest chance of detecting a mutation, as the expense
of analysing rarely-causative genes was not justified by the
low mutation detection rate per additional gene analysed.
However, this has changed with the introduction of next-
generation sequencing, which allows cost-effective ana-
lysis of many genes together, using approaches including
(1) sequencing of large panels of genes, (2) sequencing of
all coding exons in the genome, or (3) sequencing of entire
genomes. At present, a common approach uses next-gen-
eration sequencing to screen exons of panels of genes
causally associated with specific conditions or groups of
conditions. These new approaches hold the prospect of
substantially increasing the mutational pick-up rate for
HSP patients. Once fully integrated into molecular diag-
nostic services, it is possible to envisage that genetic test-
ing could be introduced at an early stage in patient work-
up, perhaps avoiding the need for other costly or painful
investigations if a definitive molecular genetic diagnosis is
made.
Although these developments are undeniably positive,
there are pitfalls and caveats associated with next-genera-
tion sequencing approaches. Sequence variation is very
common in the genome (for example, many millions of
single nucleotide variants have been identified) [40], with
the vast majority of these sequence changes having a
neutral effect with no clinical consequence. In addition,
many of these sequence changes are individually rare.
Thus, next-generation approaches typically detect numer-
ous rare sequence variants; the more genes that are ana-
lysed, the larger this problem becomes. A major problem
lies in deciding which, if any, of the detected sequence
changes are pathogenic. In most cases, this can be resolved
using bioinformatics and other approaches (e.g. identifying
previously reported and validated mutations, excluding
known rare population polymorphisms, determining the
likely effect on the amino acid sequence of the encoded
protein and how deleterious this effect is likely to be,
excluding mutations that do not co-segregate with disease)
[41]. However, inevitably in some cases, a single conclu-
sively pathogenic mutation cannot be identified and one or
more candidate pathogenic mutations remain. This is a
particular issue with mutations of the missense class (in
which only a single amino acid of the encoded protein is
altered), since it can be difficult to predict whether the
resulting effect on the protein will have functional conse-
quences. Such sequence changes are often reported as
variants of uncertain significance. Defining approaches to
determining which of these mutations are pathogenic will
be a major future challenge, as will be determining ethical
approaches to whether and how the uncertainty associated
with such sequence changes is reported back to patients.
In addition, exon-sequencing approaches do not detect
all mutational classes. A particular problem arises in
detecting large-scale deletions or duplications involving
whole exons, or in detecting promoter or deep intronic
mutations. This is an issue for at least some HSP genes, e.g.
whole exon deletions are a common cause of SPG4/SPAST
HSP (see above). We anticipate that in the relatively near
future this issue will be resolved by whole-genome
sequencing, which has the capacity to identify large dele-
tions/duplications, as well as promoter and deep intronic
mutations. In a research setting, genome sequencing may
also allow identification of causative mutations in genes
that have not previously been associated with the disease
under consideration. In the meantime, additional testing for
deletions/duplications should be considered in selected
genes for appropriate patients, prioritised based on clinical
features, in whom mutations have not been identified in
exon-sequencing panels.
High-throughput sequencing approaches also may
present ethical issues if so-called ‘‘incidental findings’’
(clinically relevant changes in genes unrelated to the con-
dition being tested) are detected. These are particularly
important when whole-exome or whole-genome approa-
ches are taken, where, given sufficient numbers of tested
subjects, it is inevitable that other potentially clinically
significant abnormalities, e.g. mutations in cancer predis-
posing genes or detection of carrier status for autosomal
recessive disease, will be detected. Whether and how such
findings are reported back to patients requires careful
consideration of their clinical validity and utility, and the
ethical issues surrounding this are currently a topic of much
debate [42].
Finally, while next-generation sequencing approaches
have the potential to increase rates of molecular genetic
diagnosis in HSP, they do not remove the need for careful
phenotyping––this is still important, as it can help to focus
bioinformatics analysis onto the most relevant genes.
Careful phenotyping may also better define the clinical
spectrum associated with pathogenic mutations in particu-
lar genes.
Rehabilitation and therapy for HSP patients
People with HSP complain of muscle stiffness, pain, spasms
and cramps, tripping over their toes due to weakness of
ankle dorsiflexion and hip flexion, loss of balance, effortful
walking and progressively more flexed standing posture.
Eventually, walking becomes impossible for some patients
due to a combination of (a) spasticity, (b) weakness,
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particularly of ankle dorsiflexion, leading to (c) loss of
range of movement at ankle, knee and hip, making it
impossible to stand straight, and (d) loss of motor control
leading to delayed postural reflexes and loss of balance.
A home exercise programme supervised by a physio-
therapist, concentrating on stretches to maintain range of
movement and reduce spasticity, accompanied by balance
exercises in patients with more advanced disease, is the
cornerstone of management. This is usually supported by a
trial of oral muscle relaxants such as Baclofen, Tizanidine,
or Gabapentin/Pregabalin. Problematic spasticity in spe-
cific groups of muscles, most commonly in the ankle
plantarflexors and hip adductors, may be treated by Botu-
linum toxin without the risk of sedation associated with
oral muscle relaxants [43]. The role of Botulinum toxin is
to support and facilitate stretching and splinting, rather
than to replace it. Functional electrical stimulation (FES) is
popular among patients and physiotherapists and is as
effective as simple off the shelf ankle foot orthoses (AFOs)
in the early stages before calf shortening has developed:
after that, FES is less useful as it cannot provide support or
compensation during stance phase [44–46].
Intrathecal Baclofen, delivered by an implanted pump, is
the most effective method of reducing very high tone in the
lower limbs, and can bring immediate relief of pain and
improvement in sitting posture, along with a reduction in
effort transferring from wheelchair to bed or car [47].
Effective control of muscle tone often improves quality of
sleep for the patient and their partner, and permits
stretching and splinting with the aim of preventing further
deterioration of flexion contractors. The question of when
to start intrathecal baclofen in this condition has not been
addressed by published trials. While most often performed
much later in the disease, a case can be made for
implanting a pump relatively early to prevent the devel-
opment of contractures, with a view to maintaining upright
gait and retaining the option of supporting weak knee ex-
tensors and ankle dorsiflexors with orthoses [48].
Once ankle contractures have developed, and people can
no longer stand with knees and hips straight while their heels
are on the ground, heel wedging needs to be incorporated into
shoes or AFOs to compensate. The lighter ‘‘off the shelf’’
AFOs, or FES of the peroneal nerve, are no longer appro-
priate in this situation as these only prevent passive plan-
tarflexion during the swing phase of gait and are not designed
to stabilise the foot and ankle during the stance phase of gait.
The necessary custom moulded AFOs with compensatory
heel wedging will often not fit in patients’ usual shoes; if
larger trainers are impractical, expensive bespoke footwear
may be required. Custom AFOs may also be designed to
compensate for weak knee extensors using the ground
reaction force to hold the lower leg in a more vertical posi-
tion, but this is only possible if the knee still extends fully.
Conclusion
The last decade has seen astonishing progress in the
identification of HSP genes. Coupled to the introduction of
high-throughput sequencing approaches, we are quickly
moving towards the ideal situation where every HSP
patient will have a defined molecular diagnosis if they
choose to have it. This will give important immediate
benefits to HSP families, including diagnostic certainty,
prevention of unnecessary additional investigations and
accurate risk prediction for clinically unaffected family
members. In the future, as HSP therapies emerge, it may
also be a pre-requisite for the personalised selection of
appropriate treatment. In the meantime, it is important that
supportive therapy, which can make a real difference to
patients’ lives, is not neglected.
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